Cholesterol Clinical Trials in Beijing, Beijing Municipality
7 recruitingBeijing, Beijing Municipality, China
Showing 1–7 of 7 trials
Recruiting
Phase 2Phase 3
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
Heterozygous Familial Hypercholesterolemia (HeFH)
Merck Sharp & Dohme LLC153 enrolled24 locationsNCT07058077
Recruiting
Phase 3
A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyperlipidemia
Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.760 enrolled2 locationsNCT07421297
Recruiting
Phase 3
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
Familial Hypercholesterolemia - Homozygous
Novartis Pharmaceuticals9 enrolled18 locationsNCT06597006
Recruiting
Phase 3
Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
Familial Hypercholesterolemia - Heterozygous
Novartis Pharmaceuticals51 enrolled66 locationsNCT06597019
Recruiting
Phase 3
A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia
DyslipidemiasHypercholesterolemia
Hasten Biopharmaceutical Co., Ltd.210 enrolled18 locationsNCT06568471
Recruiting
Phase 3
Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia
Primary Hypercholesterolaemia and Mixed Dyslipidemia
Shanghai Junshi Bioscience Co., Ltd.582 enrolled1 locationNCT05621070
Recruiting
Not Applicable
LDL Cholesterol TARGETs in OLDer Patients (Age≥75 Years) With ASCVD (TARGET OLD)
Older PatientsAtherosclerotic Cardiovascular DiseaseLDL Cholesterol
China National Center for Cardiovascular Diseases4,200 enrolled1 locationNCT05765370